NAD-supplementation in Drug naïve Parkinson's Disease
NCT03816020 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2020-02-12
Summary
1. Primary objective: Determine if NR has an impact on the neurometabolic profile of patients with PD as measured by \[18F\]Fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET).
2. Secondary objective: Determine whether high dose oral NR improves motor symptoms associated with PD.
3. Tertiary objectives: determine whether high dose oral NR rectifies NAD metabolism and increases NAD levels in body fluids and muscle tissue.
Conditions
- Parkinson Disease
- Neurodegenerative Diseases
Interventions
- DIETARY_SUPPLEMENT
-
Nicotinamide Riboside
Nicotinamide Riboside capsules 250mg x 2 BID
- OTHER
-
Placebo
Placebo capsules BID
Sponsors & Collaborators
-
Haukeland University Hospital
lead OTHER
Principal Investigators
-
Charalampos Tzoulis, PhD · Nevro-Sysmed
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-03-09
- Primary Completion
- 2020-02-10
- Completion
- 2020-02-10
Countries
- Norway